Stroke 2021 Jul 27:STROKEAHA120033862. Epub 2021 Jul 27.
Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Switzerland. (L.M., A.A.P., F.S., V.L.A., C.T., S.T., B.W., J.F., A.Z., T.D., U.F., N.P., G.M.D.M., H.G., L.H.B., P.A.L., S.T.E.).
Background And Purpose: Data on the effectiveness and safety of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients with stroke attributable to atrial fibrillation (AF) who were dependent on the daily help of others at hospital discharge are scarce.
Methods: Based on prospectively obtained data from the observational Novel-Oral-Anticoagulants-in-Ischemic-Stroke-Patients-longterm registry from Basel, Switzerland, we compared the occurrence of the primary outcome-the composite of recurrent ischemic stroke, major bleeding, and all-cause death-among consecutive patients with AF-stroke treated with either VKAs or DOACs between patients dependent (defined as modified Rankin Scale score, 3-5) and patients independent at discharge. We used simple, adjusted, and weighted Cox proportional hazards regression to account for potential confounders. Read More